tiprankstipranks
SciSparc and Clearmind Innovate Mental Health Treatment
Company Announcements

SciSparc and Clearmind Innovate Mental Health Treatment

SciSparc Ltd. (SPRC) has released an update.

Pick the best stocks and maximize your portfolio:

SciSparc Ltd., in collaboration with Clearmind Medicine Inc., has announced the publication of an international patent application for a novel MDMA-based treatment aimed at improving safety and efficacy in mental health and addiction therapies. Their combined approach seeks to address FDA concerns by integrating MDMA with N-Acylethanolamines, promising advancements in clinical treatments of mental disorders and addictions. SciSparc, a clinical-stage pharmaceutical company, continues to focus on cannabinoid-based pharmaceuticals, while Clearmind concentrates on psychedelic-derived therapeutics for underserved health problems.

For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskSciSparc Announces Spin-Off Plans with Miza III Ventures
TheFlySciSparc amends non-binding LOI to spin-off advanced clinical stage portfolio
TipRanks Auto-Generated NewsdeskSciSparc Ltd. to Acquire AutoMax Motors Ltd.
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App